DigiMed Bayern Symposium 2022

Big Data and AI: Can medicine do the doable?

The DigiMed Bayern Symposium 2022 took place on October 6, 2022 at the Gene Center Munich.

Movie of the Deutsches Herzzentrum München about the DigiMed Bayern Symposium 2022 with interviews (in German)

Review BioM

Digitization in medicine: leveraging enormous potential: DigiMed Bayern Symposium outlines the path to a "medicine of the future"

Munich-based BioM Biotech Cluster Development GmbH and the Deutsches Herzzentrum München hosted the annual DigiMed Bayern Symposium 2022: Big Data and AI: Can Medicine Do the Doable? on October 6 at the Gene Center Munich. This year, the DigiMed Bayern partners discussed together with top-class speakers from international politics, medical research, and industry: about successful project examples for P4 medicine, about infrastructure and pilot projects for the use of digital health data and about Germany's progress in the field of "Digital Health" in international comparison.

The Bavarian flagship project DigiMed Bayern aims to prevent heart attacks and strokes and represents data-based personalized medicine - using the widespread disease atherosclerosis as an example. The flagship project, which has been funded by the Bavarian State Ministry of Health and Care with with a total volume of 24.5 million euros since 2018, pursues as the so-called P4 medicine. The goal is a personalized (tailored), preventive (avoiding), predictive (predicting) and participatory (participating) medicine of the future.

Klaus Holetschek, Bavaria's Minister of State for Health and Care, welcomed the audience in a video message and [...]

>>> to the entire press release <<<


Presentations (PDF download⇓)

Keynote: Better health and wealth for the Danish citizens through the primary and secondary use of data, Lisbeth Nielsen - Director General, Danish Health Data Authority

Welcome & Philosophy of DigiMed Bayern, Prof. Dr. Heribert Schunkert - Medical Director, German Heart Centre Munich

Prevention: early diagnosis and treatment of children with Familial Hypercholesterolemia, the VRONI-study, Dr. Raphael Schmieder - German Heart Centre Munich

Personalised medicine in coronary artery disease is sustainably improved by combining clinical and OMICs data, Dr. Moritz von Scheidt - German Heart Centre Munich

Predictive Epidemiological studies enhanced with molecular phenotypes, Prof. Dr. Annette Peters - Director of the Institute of Epidemiology, Helmholtz Munich

Participatory: HerzFit: Generation of a Health App, Dr. Fabian Starnecker, German Heart Centre Munich & Lara Marie Reimer, Technical University of Munich

Bavarian Cloud for Health Research-a collaborative infrastructure for biomedicine, Dr. Christian Mertes, Technical University of Munich, Munich Data Science Institute, Workflow coordinator German Human Genome-Phenome Archive

Enabling health data for primary and secondary use in Bavaria and in GAIA-X: Team-X project, Prof. Dr. Bjoern Eskofier, Machine Learning and Data Analytics (MaD) Lab,Friedrich-Alexander-Universität Erlangen-Nürnberg

AWS Healthcare: A view on unlocking the potential of healthcare data in Germany and around the world, Joanna Wardzinski, Health Tech Lead & Operations, International, AWS Healthcare

The Finnish pathway towards the legislative framework for secondary use of social and health data, Dr. Päivi Sillanaukee, Ambassador for Health and Wellbeing, Ministry for Foreign Affairs of Finland

Secondary use of health data – a pharma perspective, Dr. Henning Düwert, Senior Counsel Pharmaceutical Law, Verband Forschender Arzneimittelhersteller e.V.


Picture gallery

 

Copyright: BioM

Please contact us should you require higher resolution photos: presse@remove-this.bio-m.org.


Program (print version⇓)

 

9:00 - 9:50

Welcome & Intro to DigiMed Bayern & Keynote

9:00-9:05

Welcome at the Gene CenterProf. Dr. Karl-Peter Hopfner, Director Gene Center Munich

 

Welcome & Philosophy of DigiMed

Prof. Dr. Heribert Schunkert, Clinical Director, German Heart Centre Munich

 

Welcome Video Message

Klaus Holetschek, State Minister, Bavarian Minister of Health and Care

 

Keynote

 

Lisbeth Nielsen, Director General, Danish Health Data Authority

9:50-11:30

Session A:

P4 Medicine examples from DigiMed Bayern

Moderator:

Prof. Dr. Heribert Schunkert, German Heart Centre Munich

 

Personalised medicine in coronary artery disease is sustainably improved by combining clinical and OMICs data

Dr. Moritz von Scheidt, German Heart Centre Munich

 

Preventive: Early diagnosis and treatment of children with Familial Hypercholesterolemia, the VRONI-study

Dr. Raphael Schmieder und Dr. Holger Prokisch, German Heart Centre Munich

 

Predictive: Epidemiological studies enhanced with molecular phenotypes

Prof. Dr. Annette Peters, Director of the Institute of Epidemiology, Helmholtz Zentrum Munich and and Principal Investigator, German National Cohort (NAKO)

 

Participatory: HerzFit: Generation of a Health App

Dr. Fabian Starnecker, German Heart Centre Munich & Lara Marie Reimer, Technical University of Munich

 

Heart(s) of the Matter: P4-Medicine from the Perspective of Ethics

Dr. Therese Feiler, Ludwig-Maximilians-University, Institut Technik-Theologie-Naturwissenschaften

11:30-12:45

 Lunch & Networking

 

12.45-14.05

Session B:

Infrastructure & Pilot Projects

Moderator:

Dr. Jens Wiehler, BioM Biotech Cluster Development GmbH

 

Bavarian Cloud for Health Research - a collaborative infrastructure for biomedicine

Dr. Christian Mertes, Workflow coordinator German Human Genome-Phenome Archive, Munich Data Science Institute, Technical University of Munich

 

Enabling health data for primary and secondary use in Bavaria and in GAIA-X: Team-X project

Prof. Dr. Björn Eskofier, Friedrich-Alexander-University Erlangen-Nürnberg

 

Secondary data use supported by national infrastructure

Stefan Höcherl, Director Strategy and Standards, gematik GmbH

 

Bavarian State: Our vision of data driven health, care and R&D

Dr. Thomas Huber, Head of Department 1, Bavarian State Ministry of Health and Care

14:05-14:30

 Coffee Break

 

14:30-16:00

Session C:

International Benchmarking

Moderator:

Prof. Dr. Horst Domdey, BioM Biotech Cluster Development GmbH

 

AWS Healthcare: Our view on the German healthcare market and secondary data use in international comparison

Joanna Wardzinski, Health Tech Lead & Operations, International, AWS Healthcare

 

The Finnish pathway towards the legislative framework for secondary use of social and health data

Dr. Päivi Sillanaukee, Ambassador for Health and Wellbeing, Ministry for Foreign Affairs of Finland

 

Secondary use of patient data from the perspective of the research-based pharmaceutical industry

 

Dr. Henning Düwert, Senior Counsel Pharmaceutical Law, Verband Forschender Arzneimittelhersteller e.V.

 

Overall discussion with audience & closing remarks

All, Prof. Dr. Horst Domdey and Prof. Dr. Heribert Schunkert

16:00-16:30

 Networking, drinks & fingerfood


Background information

The flagship project DigiMed Bayern demonstrates feasibility of P4-medicine in Bavaria and Germany, from multilayered big data research projects all the way to large scale initiatives preventing atherosclerotic diseases, such as coronary heart disease and stroke. DigiMed Bayern has a runtime from 2018 to 2024 and it is funded with approx. € 25 million by the Bavarian State Ministry of Health and Care. It generated highly utilized Apps for calculating and minimizing risk of cardiovascular diseases, implemented state-wide measures for preventing atherosclerosis at young age, and produced comprehensive datasets of patients diagnosed with coronary disease, or with its genetic risk factors. The data are enriched by state-of-the-art multi-dimensional characterization (-omics technologies) for gaining new insights into the molecular mechanisms leading to the diseases. For the integrative analysis of the resulting "Big Data", a compliant, secure and sustainable IT-infrastructure is fundamentally designed and implemented. Finally, as we will show, patients and persons at risk do and will further benefit from advancements in disease risk prediction, diagnosis, targeted prevention and treatment.

funded by


Scientific Management


Executive Management